University of Thessaly (UTH)
Διερεύνηση πιθανής ενθεσοπάθειας σε ασθενείς με ψωρίαση συγκεκριμένων εντοπίσεων, με σύγχρονες απεικονιστικές μεθόδους (High resolution MRI ή/και Ultrasound), πριν και μετά την αγωγή με βιολογικούς παράγοντες ή απρεμιλάστη
Abstract
dc:descriptionIntroduction: Psoriasis is a chronic inflammatory disease due to malfunction of T- lymphocytes. It affects 1-3% of the general population worldwide and is equally common in men and women. There are various characteristic clinical forms of psoriasis. Chronic scaly plaques are commonly seen on the elbows, knees and scalp, while psoriatic arthritis occurs in up to 30% of patients. Aim: It was to identify initial enthesopathy lesions in patients with psoriasis and predisposing factors for the appearance of psoriatic arthritis (e.g. nail psoriasis, psoriasis in the mesogluteal fissure, on the scalp) before the start of medication with biological therapy " secukinumab" or apremilast. With the help of imaging techniques, the course and progress of the patients under treatment was monitored at 0 and 16 weeks. Method: The study included 76 patients of all ages who were followed at the outpatient clinics or in the Dermatology Clinic of the University Hospital of Larisa during 2018/2019. The PASI score, NAPSI score, Caspar Criteria and the DLQI were used for the classification and the follow-up of the patients. Prior to inclusion in the study, patients signed a consent form. After signing the consent form, the patients underwent a simple biochemical and hematological test and specific indicators of psoriasis severity were recorded (PASI score, NAPSI score and the DLQI score)Results: Significant differences were found between the two groups of patients in all three indicators: The non-parametric Mann-Whitney U-test shows that the percentage change of PASI and DLQI in the two drugs groups presents a statistically significant difference (p-value < 0.001). From the parametric T-test it emerged that the percentage change of NAPSI in the two drugs presents a statistically significant difference (p-value = 0.003). Regarding imaging, the Two-sample Z test showed that after administration there is a statistically significant difference only in the swelling for the two populations that received the different drugs (p-values = 0.004 < 0.007). Conclusion: The present study highlights the superiority of the drug "secukinumab" over the drug "apremilast" in PASI, DLQI, NAPSI parameters, and in imaging techniques in patients with diagnosed psoriasis and predisposing factors for psoriatic arthritis, but without established psoriatic arthritis. The findings of the present study strengthen the view for early intensive treatment with secukinumab in people with severe psoriasis, which could potentially modify the natural course of the disease and even prevent the development of PsA, resulting in better patient outcomes.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2024
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Alifakioti, Dimitra
- Αληφακιώτη, Δήμητρα
Subjects
dc:subject × 15Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/56947